What question did this study set out to answer?

To compare the effectiveness of dupilumab and tralokinumab in treating atopic dermatitis using real-world data.

April 15, 2026Open Access

Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay

Key Points

To compare the effectiveness of dupilumab and tralokinumab in treating atopic dermatitis using real-world data.
Conducted a real-world comparison study using propensity score adjustments.
Analyzed effectiveness based on EASI and NRS-pruritus scores.
Considered treatment discontinuation rates in assessments.
Dupilumab demonstrated superior effectiveness compared to tralokinumab.
Small differences in EASI and NRS-pruritus for ongoing respondents.
More notable differences seen with specific treatment targets for EASI and pruritus.

Abstract

In this real-world comparison, dupilumab provided superior effectiveness compared with tralokinumab. In responders continuing treatment, EASI and NRS-pruritus differences were small. More substantial differences were observed when treatment targets EASI ≤ 7 and NRS-pruritus ≤ 4, and discontinuation rates were taken into account.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Lian F. van der Gang

Nicolaas P. A. Zuithoff

I Haeck

Journals

Journal of the European Academy of Dermatology and Venereology

Actions

Institutions

Radboud University Nijmegen

University Medical Center Utrecht

Maastricht University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study